Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse/refractory Hodgkin lymphoma: Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)
Most patients suffering from classical Hodgkin's lymphoma (cHL) can be treated successfully with standard chemo- and/or radiotherapy, with 70% of them being alive 10 years after diagnosis. The gold standard treatment for patients that fail first-line treatment is high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autoHSCT).1-4 Patients who fail autoHSCT (or at least two prior lines of therapy) may be treated with brentuximab vedotin (Bv); however, in many patients the disease will progress, with a median overall survival (OS) of approximately 22 months.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Carmen Mart ínez, Cecilia Carpio, Inmaculada Heras, Eduardo Ríos-Herranz, Joan Buch, Antonio Gutierrez, Samuel Romero, Izaskun Zeberio, Irene García-García, Antonia Rodriguez-Izquierdo, Rosalía Alonso, Joan Bargay, Cristina Barrenetxea, Eva Domingo-D Source Type: research
More News: Biology | Bone Marrow Transplant | Chemotherapy | Hematology | Hodgkin's Disease | Lymphoma | Spain Health | Stem Cell Therapy | Stem Cells | Transplants